The Challenges Faced in Developing Novel Drug Radiation Combinations in Non-small Cell Lung Cancer

S Harrow; Gerry Hanna; C Faivre-Finn; F McDonald; A J Chalmers

doi:10.1016/j.clon.2016.08.004

The Challenges Faced in Developing Novel Drug Radiation Combinations in Non-small Cell Lung Cancer

S Harrow, Gerry Hanna, C Faivre-Finn, F McDonald, A J Chalmers

School of Medicine, Dentistry and Biomedical Sciences

Research output: Contribution to journal › Article › peer-review

6 Citations (Scopus)

353 Downloads (Pure)

Abstract

Lung cancer is the most common cancer diagnosed in the UK. Outcomes for patients with this disease remain poor and new strategies to treat this disease require investigation. One potential option is to combine novel agents with radiotherapy in clinical studies. Here we discuss some of the important issues to consider when combining novel agents with radiotherapy, together with potential solutions as discussed at a recent Clinical Translational Radiotherapy Group (CTRad) workshop.

Original language	English
Pages (from-to)	720-725
Number of pages	6
Journal	Clinical oncology (Royal College of Radiologists (Great Britain))
Volume	28
Issue number	11
Early online date	31 Aug 2016
DOIs	https://doi.org/10.1016/j.clon.2016.08.004
Publication status	Published - Nov 2016

Keywords

Lung Cancer
Systemic Therapy
DNA Damaging Agents
Radiotherapy
Chemoradiotherapy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.clon.2016.08.004Licence: Unspecified

The Challenges Faced in Developing Novel Drug Radiation Combinations in Non-small Cell Lung Cancer
Copyright 2016 Elsevier. This is an open access article published under a Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits distribution and reproduction for non-commercial purposes, provided the author and source are cited.
Accepted author manuscript, 293 KBLicence: CC BY-NC-ND

Radiotherapy in lung cancer – novel approaches and new horizons
Gerry Hanna (Invited speaker)
29 Sep 2017
Activity: Talk or presentation types › Invited or keynote talk at national or international conference
Invited presentation to LORD subgroup at BTOG on the proposed CONCORDE study
Gerry Hanna (Invited speaker)
26 Jan 2017
Activity: Talk or presentation types › Invited or keynote talk at national or international conference

Cite this

@article{5fec81f70cbb451b949a464c14ab2e1e,

title = "The Challenges Faced in Developing Novel Drug Radiation Combinations in Non-small Cell Lung Cancer",

abstract = "Lung cancer is the most common cancer diagnosed in the UK. Outcomes for patients with this disease remain poor and new strategies to treat this disease require investigation. One potential option is to combine novel agents with radiotherapy in clinical studies. Here we discuss some of the important issues to consider when combining novel agents with radiotherapy, together with potential solutions as discussed at a recent Clinical Translational Radiotherapy Group (CTRad) workshop.",

keywords = "Lung Cancer, Systemic Therapy, DNA Damaging Agents, Radiotherapy , Chemoradiotherapy",

author = "S Harrow and Gerry Hanna and C Faivre-Finn and F McDonald and Chalmers, {A J}",

year = "2016",

month = nov,

doi = "10.1016/j.clon.2016.08.004",

language = "English",

volume = "28",

pages = "720--725",

journal = "Clinical Oncology",

issn = "0936-6555",

publisher = "Elsevier",

number = "11",

}

TY - JOUR

T1 - The Challenges Faced in Developing Novel Drug Radiation Combinations in Non-small Cell Lung Cancer

AU - Harrow, S

AU - Hanna, Gerry

AU - Faivre-Finn, C

AU - McDonald, F

AU - Chalmers, A J

PY - 2016/11

Y1 - 2016/11

N2 - Lung cancer is the most common cancer diagnosed in the UK. Outcomes for patients with this disease remain poor and new strategies to treat this disease require investigation. One potential option is to combine novel agents with radiotherapy in clinical studies. Here we discuss some of the important issues to consider when combining novel agents with radiotherapy, together with potential solutions as discussed at a recent Clinical Translational Radiotherapy Group (CTRad) workshop.

AB - Lung cancer is the most common cancer diagnosed in the UK. Outcomes for patients with this disease remain poor and new strategies to treat this disease require investigation. One potential option is to combine novel agents with radiotherapy in clinical studies. Here we discuss some of the important issues to consider when combining novel agents with radiotherapy, together with potential solutions as discussed at a recent Clinical Translational Radiotherapy Group (CTRad) workshop.

KW - Lung Cancer

KW - Systemic Therapy

KW - DNA Damaging Agents

KW - Radiotherapy

KW - Chemoradiotherapy

U2 - 10.1016/j.clon.2016.08.004

DO - 10.1016/j.clon.2016.08.004

M3 - Article

C2 - 27591000

VL - 28

SP - 720

EP - 725

JO - Clinical Oncology

JF - Clinical Oncology

SN - 0936-6555

IS - 11

ER -

The Challenges Faced in Developing Novel Drug Radiation Combinations in Non-small Cell Lung Cancer

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Activities

Radiotherapy in lung cancer – novel approaches and new horizons

Invited presentation to LORD subgroup at BTOG on the proposed CONCORDE study

Cite this